The China-headquartered CRDMO filed a complaint with the U.S. District Court for the District of Columbia challenging the designation by the Defense Department.
The financing will support pipeline expansion across biosimilars, innovative medicines, and animal health, as well as development of proprietary rapid-production technologies.
The in-house capability supports an integrated path from DNA to IND submission, eliminating external handoffs for biologics developers, according to the company.
